Assessing Suicide Risk in Airline Pilots With Major Depression

Abstract: The US Federal Aviation Administration (FAA) and European regulators permit the use of selective serotonin reuptake inhibitors (SSRIs) and recently approved antidepressants in pilots with major depression (MD). Current protocols allow return to flying after approximately 1 month after recovery in Europe and after at least 6 months in the United States. Evidence suggests that suicide risk, including unrecognized risk, may persist for up to 1 year after treatment initiation, with variation between antidepressants. Cognitive dysfunction may also outlast recovery. Extending an initial grounding period could reduce pilot suicidality as a distinct flight safety risk, support accurate differential diagnosis, and enable drug-specific guidance. Decreasing barriers to seeking help for mental health concerns and strengthened monitoring protocols may better safeguard pilot well-being.